Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.73 +9.3% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.73 +9.3% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
Other Routine +

TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications

TempraMed Technologies Ltd.

By The Northwire Desk — AI Analysis May 22, 2026 · 11:58 VIVI · 0.7 TempraMed Technologies Ltd.
Executive Summary
  • TempraMed Technologies was featured on The Dr. Phil Show in a national US broadcast segment titled "Dose of Reality: The Truth About Temperature."
  • The segment highlights risks associated with temperature exposure for insulin, GLP-1 medications, biologics, and epinephrine during travel or daily activities.
  • TempraMed's FDA-registered thermal insulation devices (VIVI Cap, VIVI Cap Smart, VIVI Epi, VIVI Med) were presented as solutions that function without external power.
  • The feature is part of a broader strategy to drive awareness through patient education and physician engagement.
  • CEO Ron Nagar emphasized the platform allows for national education on preventable risks regarding medication storage.
Material Impact
  • Immediate Financial Impact: None. This is a brand awareness event with no disclosed revenue, contract value, or order volume associated with the broadcast.
  • Strategic Alignment: Consistent with previous announcements (e.g., Jan 2026 product launches, Dec 2025 manufacturing expansion) regarding patient education and market penetration.
  • Market Context: The stock has been trending downward since January 2026 highs ($1.30), currently consolidating near May lows ($0.59). While positive sentiment is expected from media features, the lack of financial metrics limits material upside in isolation.
  • Comparison to Recent History: Follows a period of significant financing activity (May 14 RPA) which diluted future revenue streams. This PR event does not offset the fundamental cost of capital incurred via the Royalty Purchase Agreement.
VIVI · Price
Company Overview
  • Company: TempraMed Technologies Ltd. (CSE: VIVI).
  • Flagship Project: Temperature-controlled medication storage devices designed to protect insulin, GLP-1s, biologics, and epinephrine from heat exposure without batteries or external power.
  • Product Portfolio:
    • VIVI Cap / VIVI Cap Smart (Insulin/GLP-1 pens).
    • VIVI Epi (Epinephrine auto-injectors).
    • VIVI Med (Vials/Biologics).
    • VIVI Box (Multi-medication storage, planned late 2026 launch).
  • Technology: Patented deep-vacuum insulator combined with phase-change material. FDA registered devices.
  • Commercial Status: Active distribution in Israel, Turkey, Korea, Benelux, and US retail channels (Amazon, Target, etc.).
Read the original news release →

More from TempraMed Technologies Ltd.

Jun 30, 2026 · 03:06

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

M&A / Property Jun 26, 2026 · 16:11

Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.

M&A / Property Jun 04, 2026 · 07:01

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Other May 14, 2026 · 03:01

Indian patent adds IP depth but revenue-sharing financing signals cash crunch

Financings Apr 07, 2026 · 07:01

Brazilian patent bolsters TempraMed’s IP moat ahead of VIVI Box launch.

M&A / Property Mar 30, 2026 · 16:52

Tempramed signs LOI for Panama distribution expansion

M&A / Property